AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11403808 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 504
Study 11403808 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (surgery)
Number of subjects: 504
Study 9404904 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg qd)
Number of subjects: 469
Study 9404904 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg bid)
Number of subjects: 469
Study 9404904 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 469
Study 9404904 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 469
Study 12959299 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily
Number of subjects: 19
Study 12959299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3327149 — intervention group
Group type: EXPERIMENTAL
Intervention: b.i.d. (2 x 500 mg)
Number of subjects: 261
Study 3327149 — intervention group
Group type: EXPERIMENTAL
Intervention: q.i.d. (4 x 250 mg)
Number of subjects: 261
Study 30826377 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic Model for Comparator Selection in Health-Related Behavioral Trials
Number of subjects: 0
Study 30116106 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated-Sprint Training (RSH)
Number of subjects: 11
Study 30116106 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training in Hypoxia (SIH)
Number of subjects: 11
Study 26818599 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer reminders integrated in electronic patient records (EPR) for PVC management
Number of subjects: 626
Study 26818599 — intervention group
Group type: COMPARATOR
Intervention: Control group without computer reminders
Number of subjects: 626
Study 26818599 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer reminders integrated in EPR
Number of subjects: 626
Study 24552468 — intervention group
Group type: EXPERIMENTAL
Intervention: LED group (7 patients) - LED device at a wavelength of 626 nm, applied for 20 min over the surgical area, three times a week for 3 weeks starting from the operation day.
Number of subjects: 15
Study 24552468 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 patients) - No specific intervention details provided.
Number of subjects: 15
Study 24552468 — intervention group
Group type: EXPERIMENTAL
Intervention: LED group (7 patients) - Evaluation of biochemical markers (IL-1β, TGF-β, PGE2, NO) in peri-implant crevicular fluid (PICF).
Number of subjects: 15
Study 22767614 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia Screening Implementation programme (yearly chlamydia screening tests)
Number of subjects: 317304
Study 22767614 — intervention group
Group type: COMPARATOR
Intervention: Control group (invited at the end of round two of the intervention)
Number of subjects: 317304
Study 22767614 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 317304
Study 19715803 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted total gastrectomy (LATG)
Number of subjects: 131
Study 17690595 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (mean maximally tolerated dose: 25.0 mg, standard deviation=8.4)
Number of subjects: 29
Study 17690595 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 29
Study 16303616 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril plus prednisone and cyclophosphamide
Number of subjects: 18
Study 16303616 — intervention group
Group type: COMPARATOR
Intervention: Prednisone plus cyclophosphamide
Number of subjects: 18
Study 11756067 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw green banana flour (RBF) 30 g/d
Number of subjects: 17
Study 11756067 — intervention group
Group type: COMPARATOR
Intervention: Cooked green banana flour (CBF) 30 g/d
Number of subjects: 17
Study 11756067 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-polysaccharide-free diet with RBF 30 g/d
Number of subjects: 17
Study 9840304 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole
Number of subjects: 310
Study 9840304 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fundic wrap
Number of subjects: 310
Study 9840304 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial fundoplication
Number of subjects: 310
Study 7921324 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple telephone 24-hour dietary recalls
Number of subjects: 49
Study 7921324 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face 24-hour dietary recalls
Number of subjects: 49
Study 7921324 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple 24-hour telephone dietary recalls
Number of subjects: 49
Study 2683905 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (AB) 50 mg twice daily
Number of subjects: 25
Study 2683905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 2683905 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (AB)
Number of subjects: 25
Study 1119734 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol
Number of subjects: 107
Study 1119734 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 107
Study 1119734 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Alprenolol and Propranolol
Number of subjects: 107
Study 30929458 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM) training
Number of subjects: 113
Study 30929458 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 113
Study 28542874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (160 mg starting dose, then 80 mg every 2 weeks for 12 weeks, then 80 mg every 4 weeks)
Number of subjects: 302
Study 28542874 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab (45 mg or 90 mg weight-based dosing)
Number of subjects: 302
Study 28542874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 302
Study 28542874 — intervention group
Group type: COMPARATOR
Intervention: Ixekizumab and Ustekinumab
Number of subjects: 302
Study 25145882 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoe inserts and high-load progressive strength training (unilateral heel raises with a towel under the toes), performed every second day
Number of subjects: 48
Study 25145882 — intervention group
Group type: COMPARATOR
Intervention: Shoe inserts and daily plantar-specific stretching
Number of subjects: 48
Study 23715903 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET performed on day 21 of chemoradiotherapy (4.5 MBq/kg)
Number of subjects: 57
Study 23715903 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET performed before chemoradiotherapy (PET₁)
Number of subjects: 57
Study 23715903 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET performed on day 21 of chemoradiotherapy (PET₂)
Number of subjects: 57
Study 23715903 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in SUVmax, TV₄₀, TVp, TLG₄₀ and TLGp between PET₁ and PET₂
Number of subjects: 57
Study 22273215 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified double tracks anastomosis
Number of subjects: 396
Study 22273215 — intervention group
Group type: COMPARATOR
Intervention: Esophagus‐remnant stomach direct anastomosis
Number of subjects: 396
Study 19230959 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (88 microg twice daily)
Number of subjects: 285
Study 19230959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 17335297 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 7.5mg
Number of subjects: 1195
Study 17335297 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 10mg
Number of subjects: 1195
Study 17335297 — intervention group
Group type: COMPARATOR
Intervention: amlodipine 10mg
Number of subjects: 1195
Study 17335297 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine 7.5mg and 10mg
Number of subjects: 1195
Study 17335297 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine
Number of subjects: 1195
Study 17335297 — intervention group
Group type: EXPERIMENTAL
Intervention: ivabradine and amlodipine
Number of subjects: 1195
Study 17335297 — intervention group
Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 1195
Study 15350853 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure in vivo (E; n = 25)
Number of subjects: 73
Study 15350853 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT; n = 26)
Number of subjects: 73
Study 15350853 — intervention group
Group type: COMPARATOR
Intervention: Wait‐list control (WLC; n = 22)
Number of subjects: 73
Study 16400502 — intervention group
Group type: EXPERIMENTAL
Intervention: Teeth brushing education for two years
Number of subjects: 292
Study 16400502 — intervention group
Group type: COMPARATOR
Intervention: No teeth brushing education (Control)
Number of subjects: 292
Study 10342086 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ring with 3 mm thickness
Number of subjects: 65
Study 10342086 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ring with 3.5 mm thickness
Number of subjects: 65
Study 10342086 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal ring with 4 mm thickness
Number of subjects: 65
Study 10342086 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall experience with the vaginal rings
Number of subjects: 65
Study 8726925 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg 16 h nicotine patches (LC‐15)
Number of subjects: 297
Study 8726925 — intervention group
Group type: COMPARATOR
Intervention: 25 mg 16 h nicotine patches (HC‐25)
Number of subjects: 297
Study 8726925 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg 16 h nicotine patches (HC‐15)
Number of subjects: 297
Study 1822264 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (2 mg/day)
Number of subjects: 8
Study 6124653 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta‐1‐adrenergic blockade (100 mg metoprolol)
Number of subjects: 14
Study 6124653 — intervention group
Group type: COMPARATOR
Intervention: Control (unmedicated condition)
Number of subjects: 14
Study 30810533 — intervention group
Group type: EXPERIMENTAL
Intervention: MotivATE (Web-based intervention)
Number of subjects: 313
Study 30810533 — intervention group
Group type: EXPERIMENTAL
Intervention: MotivATE (registered users)
Number of subjects: 313
Study 30810533 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 313
Study 29470854 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening program using the FRAX® risk assessment tool and bone mineral density (BMD) measures
Number of subjects: 12483
Study 29470854 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening program
Number of subjects: 12483
Study 29470854 — intervention group
Group type: COMPARATOR
Intervention: Usual management (control)
Number of subjects: 12483
Study 26409713 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen therapy
Number of subjects: 59
Study 26409713 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 59
Study 24690470 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-session school-based intervention implemented by para-professionals
Number of subjects: 329
Study 24690470 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 329
Study 23147978 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (MT)
Number of subjects: 120
Study 23147978 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (control)
Number of subjects: 120
Study 19573262 — intervention group
Group type: EXPERIMENTAL
Intervention: Reattribution training (RT)
Number of subjects: 141
Study 19573262 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (Control)
Number of subjects: 141
Study 17631786 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical adelmidrol 2% emulsion applied twice daily
Number of subjects: 20
Study 17631786 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 patches in 6 subjects with multiple lesions that had not been treated)
Number of subjects: 20
Study 16140229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 11836291 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide 3‐month depot 22.5 mg im every 12 wk for 48 wk
Number of subjects: 40
Study 10761536 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimen of mefloquine (750 mg) and quinine (600 mg)
Number of subjects: 7
Study 10761536 — intervention group
Group type: COMPARATOR
Intervention: Quinine sulfate (600 mg)
Number of subjects: 7
Study 10761536 — intervention group
Group type: COMPARATOR
Intervention: Mefloquine (750 mg) alone
Number of subjects: 7
Study 7745336 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodissection technique
Number of subjects: 104
Study 7745336 — intervention group
Group type: COMPARATOR
Intervention: Blunt dissection and ligation technique
Number of subjects: 104
Study 31914242 — intervention group
Group type: EXPERIMENTAL
Intervention: Coalition's care‐transition program
Number of subjects: 800
Study 31914242 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 800
Study 31028165 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐PSMA‐11 administered at 2 MBq per kilogram of body weight
Number of subjects: 6
Study 31028165 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐PSMA‐11
Number of subjects: 6
Study 28504321 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% intranasal phenylephrine (Group 2)
Number of subjects: 77
Study 28504321 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% intranasal phenylephrine (Group 3)
Number of subjects: 77
Study 28504321 — intervention group
Group type: COMPARATOR
Intervention: Intranasal saline (Group 1)
Number of subjects: 77
Study 25343233 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) 1000 mg infusions, two doses 2 weeks apart
Number of subjects: 25
Study 25343233 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusions), two doses 2 weeks apart
Number of subjects: 25
Study 25343233 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 25
Study 25343233 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 25
Study 24652170 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron amino acid chelate (12.5 mg of iron in 13 g of milk)
Number of subjects: 56
Study 24652170 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate (12.5 mg of iron in 13 g of milk)
Number of subjects: 56
Study 24652170 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate
Number of subjects: 56
Study 24652170 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron amino acid chelate
Number of subjects: 56
Study 24652170 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 56
Study 21355144 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint group (moxibustion at Sanyinjiao SP 6)
Number of subjects: 174
Study 21355144 — intervention group
Group type: COMPARATOR
Intervention: Non-acupoint group
Number of subjects: 174
Study 21355144 — intervention group
Group type: COMPARATOR
Intervention: Blank group
Number of subjects: 174
Study 19787753 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-donating antimicrobial dressings
Number of subjects: 213
Study 19787753 — intervention group
Group type: COMPARATOR
Intervention: Non-silver low-adherence dressings (Control)
Number of subjects: 213
Study 16942571 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 6750
Study 16942571 — intervention group
Group type: COMPARATOR
Intervention: Drugs only (Control)
Number of subjects: 6750
Study 16942571 — intervention group
Group type: EXPERIMENTAL
Intervention: Mites
Number of subjects: 6750
Study 16942571 — intervention group
Group type: EXPERIMENTAL
Intervention: Birch
Number of subjects: 6750
Study 16942571 — intervention group
Group type: EXPERIMENTAL
Intervention: Grasses
Number of subjects: 6750
Study 16942571 — intervention group
Group type: EXPERIMENTAL
Intervention: Parietaria
Number of subjects: 6750
Study 15233975 — intervention group
Group type: COMPARATOR
Intervention: Prehypertensive individuals (653 men, 535 women)
Number of subjects: 3042
Study 11508024 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound of the dentist's drill
Number of subjects: 42
Study 11508024 — intervention group
Group type: COMPARATOR
Intervention: No sound of the dentist's drill
Number of subjects: 42
Study 9237960 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 g/d olestra
Number of subjects: 100
Study 9237960 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 g/d olestra plus 1.1 mg tocopheryl acetate/g olestra
Number of subjects: 100
Study 9237960 — intervention group
Group type: COMPARATOR
Intervention: Placebo (18 g/d triglyceride)
Number of subjects: 100
Study 8513842 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg codeine
Number of subjects: 25
Study 8513842 — intervention group
Group type: COMPARATOR
Intervention: 45 mg codeine
Number of subjects: 25
Study 2880688 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.025 to 1.0 microgram/kg/min for 2 hours)
Number of subjects: 18
Study 2880688 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.50 microgram/kg/min)
Number of subjects: 18
Study 2880688 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam (doses greater than 0.25 microgram/kg/min)
Number of subjects: 18
Study 2880688 — intervention group
Group type: COMPARATOR
Intervention: Fenoldopam
Number of subjects: 18
Study 31650711 — intervention group
Group type: EXPERIMENTAL
Intervention: Vixotrigine 150 mg 3 times a day (days 16-28) with carbamazepine 100 mg twice a day (days 1-3) and 200 mg twice a day (days 4-21)
Number of subjects: 0
Study 31650711 — intervention group
Group type: EXPERIMENTAL
Intervention: Vixotrigine 150 mg 3 times a day (days 16-28) after carbamazepine discontinuation
Number of subjects: 0
Study 31650711 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine with vixotrigine
Number of subjects: 0
Study 31650711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31609706 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (Group A)
Number of subjects: 90
Study 31609706 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (Group B)
Number of subjects: 90
Study 31609706 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate pyelectasis
Number of subjects: 90
Study 31609706 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe RPD
Number of subjects: 90
Study 31609706 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathologic scintigraphies
Number of subjects: 90
Study 31609706 — intervention group
Group type: EXPERIMENTAL
Intervention: High creatinine levels (>0.6 mg/dl)
Number of subjects: 90
Study 31609706 — intervention group
Group type: EXPERIMENTAL
Intervention: Monolateral irreversible renal function impairment
Number of subjects: 90
Study 28678950 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium alendronate (ALN) gel
Number of subjects: 20
Study 28678950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25733460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy products (474 mL/d 2% milk and 170 g/d low-fat yogurt)
Number of subjects: 100
Study 25733460 — intervention group
Group type: COMPARATOR
Intervention: Sugar-sweetened products (710 mL/d nondiet soda and 108 g/d nondairy pudding)
Number of subjects: 100
Study 25733460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy products
Number of subjects: 100
Study 25733460 — intervention group
Group type: COMPARATOR
Intervention: Sugar-sweetened products
Number of subjects: 100
Study 23932217 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 13
Study 21258823 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal therapy including cognitive-behavioral therapy
Number of subjects: 166
Study 21258823 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 166
Study 19592602 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cigarette (CC, tar: 11 mg, Nic: 0.8 mg)
Number of subjects: 30
Study 19592602 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrically Heated Cigarette Smoking System (EHCSS: tar: 5 mg, Nic: 0.3 mg)
Number of subjects: 30
Study 19592602 — intervention group
Group type: COMPARATOR
Intervention: No smoking (NS)
Number of subjects: 30
Study 16415300 — intervention group
Group type: EXPERIMENTAL
Intervention: IIb/IIIa inhibitors with GuardWire embolic protection
Number of subjects: 651
Study 16415300 — intervention group
Group type: EXPERIMENTAL
Intervention: IIb/IIIa inhibitors with FilterWire embolic protection
Number of subjects: 651
Study 16415300 — intervention group
Group type: COMPARATOR
Intervention: FilterWire embolic protection without IIb/IIIa inhibitors
Number of subjects: 651
Study 16415300 — intervention group
Group type: EXPERIMENTAL
Intervention: IIb/IIIa inhibitors
Number of subjects: 651
Study 14728071 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50‐100 mg/day
Number of subjects: 9193
Study 14728071 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50‐100 mg/day
Number of subjects: 9193
Study 10619950 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact laser prostatectomy
Number of subjects: 0
Study 10619950 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 0
Study 9176466 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical GIFT using a linear everting catheter with direct falloposcopic vision
Number of subjects: 25
Study 9176466 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical GIFT using a linear everting catheter
Number of subjects: 25
Study 1492270 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of drug cream (papaverine and phentolamine)
Number of subjects: 0
Study 1492270 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment
Number of subjects: 0
Study 3754572 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients less than 35 years of age
Number of subjects: 1168
Study 3754572 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients 36 to 45 years of age
Number of subjects: 1168
Study 3754572 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients greater than 45 years of age
Number of subjects: 1168